Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: For liposarcoma (LPS), clinical course and proper treatment strategies have not been well-established. Recently, immune-checkpoint inhibitors have shown potential efficacy in LPS. We aimed to describe the clinical course of LPS and evaluate the clinical impact of programmed death-ligand 1 (PD-L1). Materials and methods: We reviewed all consecutive patients (n=332) who underwent curative-intent surgery for localized LPS at Asan Medical Center between 1989 and 2017. PD-L1 testing was performed in well-differentiated and dedifferentiated LPS. Results: The median age was 56 years with males comprising 60.8%. Abdomen-pelvis (47.6%) and well-differentiated (37.7%) were the most frequent primary site and histologic subtype, respectively. During a median follow-up of 81.2 months, recurrence was observed in 135 (40.7%), and 86.7% (117/135) were loco-regional. Well-differentiated subtype (hazard ratio [HR], 0.38), abdomen-pelvis origin (HR, 2.43), tumor size larger than 5 cm (HR, 1.83), positive resection margin (HR, 2.58), and postoperative radiotherapy (HR, 0.36) were significantly related with recurrence-free survival as well as visceral involvement (HR, 1.84) and multifocality (HR, 3.79) in abdomen-pelvis LPS. PD-L1 was positive in 31.5% (23/73) and 51.3% (39/76) of well-differentiated and dedifferentiated LPS, respectively, but had no impact on survival outcomes. Conclusion: Clinical course of LPS was heterogeneous according to histology and anatomic location. Clear resection margin was important to lower recurrence and postoperative radiotherapy might have additional benefit. A decent portion of well-differentiated and dedifferentiated LPS were positive for PD-L1, but its prognostic role was unclear. Further research is needed to determine clinical implications of PD-L1, especially for advanced-stage LPS with unmet needs for effective systemic treatment.
Abstract
Purpose: For liposarcoma (LPS), clinical course and proper treatment strategies have not been well-established. Recently, immune-checkpoint inhibitors have shown potential efficacy in LPS. We aimed to describe the clinical course of LPS and evaluate the clinical impact of programmed death-ligand 1 (PD-L1). Materials and methods: We reviewed all consecutive patients (n=332) who underwent curative-intent surgery for localized LPS at Asan Medical Center between 1989 and 2017. PD-L1 testing was performed in well-differentiated and dedifferentiated LPS. Results: The median age was 56 years with males comprising 60.8%. Abdomen-pelvis (47.6%) and well-differentiated (37.7%) were the most frequent primary site and histologic subtype, respectively. During a median follow-up of 81.2 months, recurrence was observed in 135 (40.7%), and 86.7% (117/135) were loco-regional. Well-differentiated subtype (hazard ratio [HR], 0.38), abdomen-pelvis origin (HR, 2.43), tumor size larger than 5 cm (HR, 1.83), positive resection margin (HR, 2.58), and postoperative radiotherapy (HR, 0.36) were significantly related with recurrence-free survival as well as visceral involvement (HR, 1.84) and multifocality (HR, 3.79) in abdomen-pelvis LPS. PD-L1 was positive in 31.5% (23/73) and 51.3% (39/76) of well-differentiated and dedifferentiated LPS, respectively, but had no impact on survival outcomes. Conclusion: Clinical course of LPS was heterogeneous according to histology and anatomic location. Clear resection margin was important to lower recurrence and postoperative radiotherapy might have additional benefit. A decent portion of well-differentiated and dedifferentiated LPS were positive for PD-L1, but its prognostic role was unclear. Further research is needed to determine clinical implications of PD-L1, especially for advanced-stage LPS with unmet needs for effective systemic treatment.
참고문헌 (27)
- Ducimetiere F, "Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing", PLoS One, 6, pp.e20294~ (2011)
- Jo VY, "WHO classification of soft tissue tumours : an update based on the 2013(4th)edition", Pathology, 46, pp.95~104 (2014)
- Kaushal A, "The role of radiation therapy in the management of sarcomas", Surg Clin North Am, 88, pp.629~646 (2008)
- Chung PW, "Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma : a comparison with other soft tissue sarcomas", Cancer, 115, pp.3254~3261 (2009)
- Katz D, "Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma", Clin Sarcoma Res, 2, pp.2~ (2012)
- Marshall S, "Outcome for advanced or metastatic soft tissue sarcoma of nonextremities treated with doxorubicin-based chemotherapy : a retrospective study from a single cancer institution", Sarcoma, 2018, pp.8926598~ (2018)
- "Soft tissue sarcoma (version 6.2019)" (2020)[URL]
- Jones RL, "Differential sensitivity of liposarcoma subtypes to chemotherapy", Eur J Cancer, 41, pp.2853~2860 (2005)
- D’Angelo SP, "Nivolumab with or without ipilimumab treatment for metastatic sarcoma(Alliance A091401) : two open-label, non-comparative, randomised, phase 2 trials", Lancet Oncol, 19, pp.416~426 (2018)
- Tawbi HA, "Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma(SARC028) : a multicentre, two-cohort, single-arm, open-label, phase 2 trial", Lancet Oncol, 18, pp.1493~1501 (2017)
- Powles T, "Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma : updated results from a phase 1", 2 open-label study, 2017, pp.3, e172411~
- Dalal KM, "Diagnosis and management of lipomatous tumors", J Surg Oncol, 97, pp.298~313 (2008)
- Dalal KM, "Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk", Ann Surg, 244, pp.381~391 (2006)
- Knebel C, "Prognostic factors and outcome of liposarcoma patients : a retrospective evaluation over 15 years", BMC Cancer, 17, pp.410~ (2017)
- Singer S, "Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma", Ann Surg, 238, pp.358~370 (2003)
- Anaya DA, "Multifocality in retroperitoneal sarcoma : a prognostic factor critical to surgical decision-making", Ann Surg, 249, pp.137~142 (2009)
- Kim C, "Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma", BMC Cancer, 16, pp.434~ (2016)
- D’Angelo SP, "Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment", Hum Pathol, 46, pp.357~365 (2015)
- Kim JR, "Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas", PLoS One, 8, pp.e82870~ (2013)
- Paydas S, "Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas", Med Oncol, 33, pp.93~ (2016)
- "Expression patterns of PD-L1 and PD-1 provide rationales for immune checkpoint inhi-bition in soft tissue sarcomas" (2019)[URL]
- Yan L, "Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma", Cancer Sci, 110, pp.3038~3048 (2019)
- Zhu Z, "Prognostic value of programmed death-ligand 1 in sarcoma : a meta-analysis", Oncotarget, 8, pp.59570~59580 (2017)
- Torabi A, "PD-1 and PD-L1 expression in bone and soft tissue sarcomas", Pathology, 49, pp.506~513 (2017)
- Tseng WW, "Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma", Sarcoma, 2015, pp.547460~ (2015)
- Keung EZ, "Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma", BMC Cancer, 18, pp.913~ (2018)
- Keung EZ, "Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab", Clin Cancer Res, 26, pp.1258~1266 (2020)